A Phase 4 interventional study of Selexipag and Placebo in Pulmonary Arterial Hypertension, sponsored by Actelion. Completed at 39 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-30.
Sponsored by Actelion (part of Johnson & Johnson) · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing selexipag in Pulmonary Arterial Hypertension — 1 open to participants now, 3 under way, 1 of them phase 3. selexipag · Pulmonary Arterial Hypertension.
Among the 12 studies testing selexipag in Pulmonary Arterial Hypertension, this one is the 5th largest by enrollment, is one of 2 that started in 2017, is one of 3 in phase 4, and was the 5th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →1 of the 12 studies testing selexipag in Pulmonary Arterial Hypertension is open now, in 12 countries. Recruiting first, the newest first:
Actelion · Sites in Belarus, Belgium, Bulgaria and 10 more countries
Ages 2+
By country, each count listing its studies:
selexipag: first FDA approval 2015 (UPTRAVI), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 108 is above the median of 40 across 477 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 67 across the 12 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 12 have an industry lead sponsor. The 4 most frequent:
This study is registered under Actelion, one of the names counted as Johnson & Johnson. Under that name alone:
Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.
63 studies in Pulmonary Arterial Hypertension by Johnson & Johnson: 2 open now, 5 under way, 2 of them phase 3. Of 55 finished, 33 (60%) have results posted.
Among the 63 studies in Pulmonary Arterial Hypertension by Johnson & Johnson, this one is the 18th largest by enrollment of the 51 interventional ones that give a count, is one of 4 that started in 2017, is one of 11 in phase 4, and was the 47th registered.
Johnson & Johnson’s Pulmonary Arterial Hypertension studies by the year they started, since 2003.
1 of the studies testing selexipag in Pulmonary Arterial Hypertension that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05179876Phase 3ActelionA Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing selexipag in Pulmonary Arterial Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 63 in Pulmonary Arterial Hypertension:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the effect of selexipag on the physical activity of patients with pulmonary arterial hypertension (PAH) in their daily life, by using a wearable wrist device (actigraph). The actigraph will collect data on daily life physical activity in the patient's real environment. In addition, the PAH symptoms and their impacts will be assessed by using an electronic patient reported outcome measure in the patient's real environment. Patients will be assigned randomly to either selexipag or placebo.
This study is designed as exploratory with the purpose to generate hypotheses on new endpoints
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Symptomatic pulmonary arterial hypertension (PAH) belonging to one of the following subgroups only:
With the following hemodynamic characteristics assessed by right heart catheterization (RHC) prior to randomization:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Selexipag is up-titrated from Day 1 to Week 12 to the individualized highest tolerated dose (HTD), which can range from 200 mcg b.i.d. to 1600 mcg b.i.d., in 200 mcg steps starting with 200 mcg b.i.d. Then, the dose is increased in increments of 200 mcg b.i.d., usually at weekly intervals, depending on the dose tolerability. Up-titration is followed by a stable maintenance treatment period at the highest tolerated dose, from Week 13 to Week 24.
Drug: Selexipag
Regimen and titration scheme similar to those in the selexipag group
Drug: Placebo
Film-coated tablets for oral use; one tablet (200 mcg) to eight tablets (1600 mcg) are administered depending on the individual tolerability.
Also known as: ACT-293987, Uptravi
Matching film coated tablets
Change From Baseline to Week 24 in Actigraphy Assessed Daily Life Physical Activity (DLPA) for Variables Expressed in Minutes
Change from baseline to Week 24 of the DLPA activity parameters for daily time spent in non-sedentary activity (NSA) (as defined by Freedson '98 and Koster '16) and daily time spent in moderate-to-vigorous physical activity (MVPA) as defined by Freedson '98 were reported. These variables were assessed by actigraphy and were expressed in minutes. Freedson 1998 established ranges of activity counts obtained from a hip worn accelerometer corresponding to commonly employed MET categories. Based on this work, threshold between sedentary and NSA was defined. This threshold is often referred to as Freedson's 1998 publication. Koster 2016 defined the threshold between sedentary and NSA based on wrist-worn accelerometers on non-dominant hand, respectively. Positive change from baseline means improvement.
Time frame: Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)
Change From Baseline to Week 24 in Actigraphy DLPA for Variables Expressed in Percentage (%)
Change from baseline to Week 24 of the DLPA activity parameters for daily time spent in non-sedentary activity (NSA) (Freedson '98), daily time spent in moderate-to-vigorous physical activity (MVPA) (Freedson '98) and dailytime spent in NSA (Koster '16) were reported. These variables were assessed by actigraphy and were expressed in percentage (%). Freedson 1998 established ranges of activity counts obtained from a hip worn accelerometer corresponding to commonly employed MET categories. Based on this work, threshold between sedentary and NSA was defined. This threshold is often referred to as Freedson's 1998 publication. Koster 2016 defined the threshold between sedentary and NSA based on wrist-worn accelerometers on non-dominant hand, respectively. Positive change from baseline means improvement.
Time frame: Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)
Change From Baseline to Week 24 in Actigraphy DLPA for Variables Expressed in Counts Per Minute (Counts/Minute)
Change from baseline to Week 24 of the DLPA activity parameter for total daily activities and NSA (Koster '16) were reported. These variables were assessed by actigraphy and were expressed in counts/minutes. Koster 2016 defined the threshold between sedentary and NSA based on wrist-worn accelerometers on non-dominant hand, respectively. Positive change from baseline means improvement.
Time frame: Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)
Change From Baseline to Week 24 in Actigraphy DLPA for Variables Expressed in Counts
Change from baseline to Week 24 of the DLPA activity parameters for volume of non-sedentary activity (Koster '16)were reported. These variables were assessed by actigraphy and were expressed in counts. Koster 2016 defined the threshold between sedentary and NSA based on wrist-worn accelerometers on non-dominant hand, respectively. Positive change from baseline means improvement.
Time frame: Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)
Change From Baseline to Week 24 in Actigraphy DLPA for Variable Expressed in Step Counts
Change from baseline to Week 24 of the DLPA activity parameters for number of steps during awake time were reported. These variables were assessed by actigraphy and were expressed in step counts. Positive change from baseline means improvement.
Time frame: Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)
Change From Baseline to Week 24 in Actigraphy DLPA for Variables Expressed in Step Counts/Minute
Change from baseline to Week 24 of the DLPA activity parameters for number of steps during awake time were reported. These variables were assessed by actigraphy and were expressed in step counts/minute. Positive change from baseline means improvement.
Time frame: Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)
Change From Baseline to Week 24 in Total Sleep Time (TST)
TST (in minutes) was assessed by actigraphy.
Time frame: Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)
Change From Baseline to Week 24 in Wake After Sleep Onset (WASO)
WASO (in minutes) was assessed by actigraphy.
Time frame: Baseline and Week 24 (data collection was done during 14-Days each for Baseline and for Week 24)
Change From Baseline to Week 24 in Number of Awakenings
Number of awakenings was assessed by actigraphy.
Time frame: Baseline and Week 24 (data collection was done during 14-Days each for Baseline and for Week 24)
Change From Baseline to Week 24 in Sleep Efficiency (SE)
SE (in percentage) was assessed by actigraphy. Sleep efficiency was defined as the TST divided by the time in bed (minutes) multiplied by 100. TST was the duration in minutes including REM sleep plus NREM sleep during the time spent in bed.
Time frame: Baseline and Week 24 (data collection was done during 14-Days each for Baseline and for Week 24)
Change From Baseline to Week 24 in Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Score
PAH-SYMPACT has 2 main parts: symptoms (cardiopulmonary and cardiovascular) and impact (physical impacts and cognitive/emotional). The symptom part is a questionnaire completed daily for 7 consecutive days and contains 11 items. The impact part has a 7-day recall period and is completed on 7th day of symptoms questionnaire data collection period. It contains 11 items pertaining to impact of PAH. The average Cardiopulmonary Symptoms and cardiovascular symptoms domain scores are determined based on daily scores of 6 and 5 items, respectively, reported on a 5-point Likert scale with score range from 0=best to 4=worst. The Physical impacts and Cognitive/emotional domain consists of 7 items reported on a 5-point Likert scale (from 0 to 4). The value 0 = "not at all"/"with no difficulty at all" and value 4 = "very much"/"extremely"/ "not able at all". Mean value on each of 7-day period was calculated for each specific domain score and corresponding mean change from baseline was reported.
Time frame: Baseline and Week 24
Number of Participants With Change From Baseline to Week 24 in World Health Organization Functional Class (WHO FC)
The WHO FC of pulmonary hypertension is a physical activity rating scale as follows: Class I (No limitation of physical activity); Class II (Slight limitation of physical activity); Class III (Marked limitation of physical activity); and Class IV (Inability to carry out any physical activity without symptoms). The change from baseline in WHO FC was classified into "Improved", "No change" and "Worsened" compared to baseline. Deterioration, No Change, and Improvement are based on shift of risk category (I, II, III, IV) from baseline in WHO Functional Class.
Time frame: Baseline and Week 24
Change From Baseline to Week 24 in 6-Minute Walk Distance (6MWD)
The 6MWD was the total distance walked during 6 minutes. Mean change from baseline (distance walked at Week 24 minus distance walked at baseline) was reported.
Time frame: Baseline and Week 24
Change From Baseline to Week 24 in Borg Dyspnea Score
The Borg dyspneas score was a self-rating scale to evaluate the severity of dyspnea (from 0 "no shortness of breath at all" to 10 "very, very severe / maximal") shortness of breath. It was completed immediately after the 6-minute walk test at Week 24 and at baseline. Mean change from baseline in scoring was reported.
Time frame: Baseline and Week 24
Change From Baseline to Week 24 in N-Terminal Pro B-type Natriuretic Peptide (NT-proBNP)
Change from baseline to Week 24 in NT-pro BNP levels was reported. The negative change from baseline means improvement.
Time frame: Baseline and Week 24
| Milestone | Selexipag | Placebo |
|---|---|---|
| Started | 53 | 55 |
| Completed | 50 | 54 |
| Not completed | 3 | 1 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Other | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 |
Change from baseline to Week 24 of the DLPA activity parameters for daily time spent in non-sedentary activity (NSA) (as defined by Freedson '98 and Koster '16) and daily time spent in moderate-to-vigorous physical activity (MVPA) as defined by Freedson '98 were reported. These variables were assessed by actigraphy and were expressed in minutes. Freedson 1998 established ranges of activity counts obtained from a hip worn accelerometer corresponding to commonly employed MET categories. Based on this work, threshold between sedentary and NSA was defined. This threshold is often referred to as Freedson's 1998 publication. Koster 2016 defined the threshold between sedentary and NSA based on wrist-worn accelerometers on non-dominant hand, respectively. Positive change from baseline means improvement.
| minutes | Selexipag | Placebo |
|---|---|---|
| Daily time spent in NSA (Freedson '98) | -15.2 ± 79.78 | -25.2 ± 72.47 |
| Daily time spent in MVPA (Freedson '98) | 0.2 ± 34.48 | -1.9 ± 34.26 |
| Daily time spent in NSA (Koster'16) | -0.7 ± 72.50 | -15.0 ± 62.27 |
Change from baseline to Week 24 of the DLPA activity parameters for daily time spent in non-sedentary activity (NSA) (Freedson '98), daily time spent in moderate-to-vigorous physical activity (MVPA) (Freedson '98) and dailytime spent in NSA (Koster '16) were reported. These variables were assessed by actigraphy and were expressed in percentage (%). Freedson 1998 established ranges of activity counts obtained from a hip worn accelerometer corresponding to commonly employed MET categories. Based on this work, threshold between sedentary and NSA was defined. This threshold is often referred to as Freedson's 1998 publication. Koster 2016 defined the threshold between sedentary and NSA based on wrist-worn accelerometers on non-dominant hand, respectively. Positive change from baseline means improvement.
| Percentage of daily time spent | Selexipag | Placebo |
|---|---|---|
| Daily time spent in NSA (%), Freedson '98 | 0.08 ± 7.265 | -0.10 ± 6.439 |
| Daily time spent in MVPA (%), Freedson '98 | 0.23 ± 3.342 | 0.32 ± 3.513 |
| Daily time spent in NSA (%), Koster '16 | 0.80 ± 7.158 | 0.00 ± 6.269 |
Change from baseline to Week 24 of the DLPA activity parameter for total daily activities and NSA (Koster '16) were reported. These variables were assessed by actigraphy and were expressed in counts/minutes. Koster 2016 defined the threshold between sedentary and NSA based on wrist-worn accelerometers on non-dominant hand, respectively. Positive change from baseline means improvement.
| counts/minute | Selexipag | Placebo |
|---|---|---|
| Total daily activities | 29.3 ± 337.18 | 18.8 ± 342.77 |
| NSA, Koster '16 | 36.1 ± 342.11 | 16.8 ± 351.08 |
Change from baseline to Week 24 of the DLPA activity parameters for volume of non-sedentary activity (Koster '16)were reported. These variables were assessed by actigraphy and were expressed in counts. Koster 2016 defined the threshold between sedentary and NSA based on wrist-worn accelerometers on non-dominant hand, respectively. Positive change from baseline means improvement.
| counts | Selexipag | Placebo |
|---|---|---|
| Change From Baseline to Week 24 in Actigraphy DLPA for Variables Expressed in Counts | 3898 ± 345872 | -49187 ± 343402.2 |
Change from baseline to Week 24 of the DLPA activity parameters for number of steps during awake time were reported. These variables were assessed by actigraphy and were expressed in step counts. Positive change from baseline means improvement.
| step counts | Selexipag | Placebo |
|---|---|---|
| Change From Baseline to Week 24 in Actigraphy DLPA for Variable Expressed in Step Counts | -32.4 ± 1288.64 | -170.9 ± 1076.87 |
Change from baseline to Week 24 of the DLPA activity parameters for number of steps during awake time were reported. These variables were assessed by actigraphy and were expressed in step counts/minute. Positive change from baseline means improvement.
| step counts/minute | Selexipag | Placebo |
|---|---|---|
| Change From Baseline to Week 24 in Actigraphy DLPA for Variables Expressed in Step Counts/Minute | 0.0 ± 1.25 | 0.0 ± 1.04 |
TST (in minutes) was assessed by actigraphy.
No measurements were reported for this outcome.
WASO (in minutes) was assessed by actigraphy.
No measurements were reported for this outcome.
Number of awakenings was assessed by actigraphy.
No measurements were reported for this outcome.
SE (in percentage) was assessed by actigraphy. Sleep efficiency was defined as the TST divided by the time in bed (minutes) multiplied by 100. TST was the duration in minutes including REM sleep plus NREM sleep during the time spent in bed.
No measurements were reported for this outcome.
PAH-SYMPACT has 2 main parts: symptoms (cardiopulmonary and cardiovascular) and impact (physical impacts and cognitive/emotional). The symptom part is a questionnaire completed daily for 7 consecutive days and contains 11 items. The impact part has a 7-day recall period and is completed on 7th day of symptoms questionnaire data collection period. It contains 11 items pertaining to impact of PAH. The average Cardiopulmonary Symptoms and cardiovascular symptoms domain scores are determined based on daily scores of 6 and 5 items, respectively, reported on a 5-point Likert scale with score range from 0=best to 4=worst. The Physical impacts and Cognitive/emotional domain consists of 7 items reported on a 5-point Likert scale (from 0 to 4). The value 0 = "not at all"/"with no difficulty at all" and value 4 = "very much"/"extremely"/ "not able at all". Mean value on each of 7-day period was calculated for each specific domain score and corresponding mean change from baseline was reported.
| units on a scale | Selexipag | Placebo |
|---|---|---|
| Cardiopulmonary symptoms | -0.030 ± 0.4160 | -0.080 ± 0.2564 |
| Cardiovascular symptoms | 0.010 ± 0.3522 | -0.045 ± 0.3029 |
| Physical impact | -0.043 ± 0.5932 | -0.074 ± 0.5470 |
| Cognitive/emotional impact | 0.000 ± 0.5311 | -0.090 ± 0.5992 |
The WHO FC of pulmonary hypertension is a physical activity rating scale as follows: Class I (No limitation of physical activity); Class II (Slight limitation of physical activity); Class III (Marked limitation of physical activity); and Class IV (Inability to carry out any physical activity without symptoms). The change from baseline in WHO FC was classified into "Improved", "No change" and "Worsened" compared to baseline. Deterioration, No Change, and Improvement are based on shift of risk category (I, II, III, IV) from baseline in WHO Functional Class.
| Participants | Selexipag | Placebo |
|---|---|---|
| Deterioration | 2 | 1 |
| No change | 33 | 43 |
| Improvement | 9 | 10 |
The 6MWD was the total distance walked during 6 minutes. Mean change from baseline (distance walked at Week 24 minus distance walked at baseline) was reported.
| meters | Selexipag | Placebo |
|---|---|---|
| Change From Baseline to Week 24 in 6-Minute Walk Distance (6MWD) | 18.3 ± 54.47 | 9.8 ± 60.72 |
The Borg dyspneas score was a self-rating scale to evaluate the severity of dyspnea (from 0 "no shortness of breath at all" to 10 "very, very severe / maximal") shortness of breath. It was completed immediately after the 6-minute walk test at Week 24 and at baseline. Mean change from baseline in scoring was reported.
| units on a scale | Selexipag | Placebo |
|---|---|---|
| Change From Baseline to Week 24 in Borg Dyspnea Score | -0.25 ± 2.122 | 0.37 ± 1.869 |
Change from baseline to Week 24 in NT-pro BNP levels was reported. The negative change from baseline means improvement.
| nanogram per liter (ng/L) | Selexipag | Placebo |
|---|---|---|
| Change From Baseline to Week 24 in N-Terminal Pro B-type Natriuretic Peptide (NT-proBNP) | -153.8 ± 609.32 | 81.8 ± 316.54 |
Collected over Up to 28 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Selexipag | 0/53 (0%) | 3/53 (5.7%) | 52/53 (98.1%) |
| Placebo | 0/55 (0%) | 6/55 (10.9%) | 52/55 (94.5%) |
| Event | Selexipag | Placebo |
|---|---|---|
| Atrial FlutterCardiac disorders | 1/53 | 1/55 |
| Right Ventricular FailureCardiac disorders | 1/53 | 0/55 |
| MigraineNervous system disorders | 1/53 | 0/55 |
| Vision BlurredEye disorders | 0/53 | 1/55 |
| GlossitisGastrointestinal disorders | 0/53 | 1/55 |
| PneumoniaInfections and infestations | 0/53 | 1/55 |
| Multiple Sclerosis RelapseNervous system disorders | 0/53 | 1/55 |
| SyncopeNervous system disorders | 0/53 | 1/55 |
| Pleural EffusionRespiratory, thoracic and mediastinal disorders | 0/53 | 1/55 |
| Thyroid Nodule RemovalSurgical and medical procedures | 0/53 | 1/55 |
| Event | Selexipag | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 41/53 | 26/55 |
| DiarrhoeaGastrointestinal disorders | 28/53 | 23/55 |
| NauseaGastrointestinal disorders | 22/53 | 15/55 |
| Pain in JawMusculoskeletal and connective tissue disorders | 20/53 | 5/55 |
| NasopharyngitisInfections and infestations | 5/53 | 14/55 |
| VomitingGastrointestinal disorders | 13/53 | 4/55 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 11/53 | 8/55 |
| Pain in ExtremityMusculoskeletal and connective tissue disorders | 11/53 | 1/55 |
| DizzinessNervous system disorders | 7/53 | 7/55 |
| Non-Cardiac Chest PainGeneral disorders | 2/53 | 7/55 |
| Age, Continuous(years) | Selexipag | Placebo | Total |
|---|---|---|---|
| Mean | 49 ± 14.75 | 49.8 ± 13.63 | 49.4 ± 14.13 |
| Sex: Female, Male(Participants) | Selexipag | Placebo | Total |
|---|---|---|---|
| Female | 35 | 42 | 77 |
| Male | 18 | 13 | 31 |
| Race (NIH/OMB)(Participants) | Selexipag | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 4 | 3 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 2 |
| White | 44 | 52 | 96 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 0 | 3 |
| Region of Enrollment(participants) | Selexipag | Placebo | Total |
|---|---|---|---|
| AUSTRIA | 0 | 1 | 1 |
| FRANCE | 2 | 0 | 2 |
| GERMANY | 6 | 5 | 11 |
| IRELAND | 1 | 1 | 2 |
| NORWAY | 0 | 1 | 1 |
| PORTUGAL | 3 | 3 | 6 |
| SWEDEN | 4 | 0 | 4 |
| SWITZERLAND | 0 | 1 | 1 |
| UNITED KINGDOM | 31 | 35 | 66 |
| UNITED STATES | 6 | 8 | 14 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2017 to primary completion in Feb 2020, 27 months.
Results were first posted in Feb 2021, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selexipag
Pulmonary Arterial Hypertension →